Join to View Full Profile
1 Baxter Pkwy# 5-2wDeerfield, IL 60015
Phone+1 847-948-4135
Dr. Lebel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Ottawa Faculty of MedicineClass of 1977, MD
Certifications & Licensure
MI State Medical License 1999 - 2019
American Board of Internal Medicine Internal Medicine
Clinical Trials
- A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG Start of enrollment: 2017 Sep 26
- A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102 Start of enrollment: 2018 Jun 18
- Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102 Start of enrollment: 2018 Sep 05
Publications & Presentations
PubMed
- 6 citationsTechniques for hyaluronidase-facilitated subcutaneous fluid administration with recombinant human hyaluronidase: the increased flow utilizing subcutaneously enabled ad...Sandra Connolly, Helen Korzemba, George Harb, Francois Lebel, Christine Syltevik
Journal of Infusion Nursing. 2011-09-01 - 46 citationsSafety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administr...George Harb, Francois Lebel, Jean P. Battikha, Jeffrey W Thackara
Current Medical Research and Opinion. 2010-01-15 - 1 citationsCryptococcal cerebrospinal fluid shunt infection treated with fluconazole.Daniel Eymard, François Lebel
The Canadian Journal of Infectious Diseases = Journal Canadien Des Maladies Infectieuses. 1993-07-01
Press Mentions
Spectrum Pharmaceuticals Announces Data from Poster Presentation for Poziotinib in NSCLC Patients with G778_P780dup HER2 Exon 20 Mutations at ESMO Congress 2022September 10th, 2022- Spectrum Pharmaceuticals Presents Late Breaker Oral Presentation of Poziotinib Data in First-Line NSCLC Patients with HER2 Exon 20 Insertion Mutations at ESMO Congress 2021September 18th, 2021
- Spectrum Pharmaceuticals Presents Additional Twice Daily Dosing Data for Poziotinib at the AACR Virtual Meeting 2021April 10th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
